We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.11% | 129.98 | 131.05 | 129.845 | 131.05 | 359,660 | 14:43:02 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Merck & Co. (MRK) on Thursday said a Phase 3 study of its cancer drug Keytruda in combination with Pfizer Inc.'s (PFE) kidney-cancer drug Inlyta met both primary endpoints.
The Kenilworth, N.J., drug maker said the combination showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival in the first-line treatment of advanced or metastatic renal cell carcinoma, the most common type of kidney cancer.
Merck said the study also met the key secondary endpoint of objective response rate, with significant improvements for the combination compared with sunitinib monotherapy.
Merck said fewer than 10% of patients diagnosed with advanced renal cell carcinoma survive for five years. The companies plan to submit the results to regulatory authorities world-wide.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2018 08:20 ET (12:20 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
